<p>Galapagos NV has announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, following the completion of works council consultations in Belgium and the Netherlands. The move affects approximately 365 employees across Europe, the U.S., and China, and will result in the closure of sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai. The company plans to provide further updates on the estimated timeline and costs of the wind-down, as well as financial guidance, during its full year 2025 earnings release and conference call in late February 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galapagos NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 1001157787) on January 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Galapagos NV to Wind Down Cell Therapy Activities and Close Multiple Sites